New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 20, 2014
10:37 EDTMDT, APA, NUAN, WMB, KMI, CCE, NI, CNP, COVOptions with increasing implied volatility
Options with increasing implied volatility: NUAN COV CCE APA CNP KMI MDT NI WMB
News For NUAN;COV;CCE;APA;CNP;KMI;MDT;NI;WMB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 24, 2015
08:02 EDTCCECoca-Cola Enterprises added to U.S. 1 List at BofA/Merrill
Subscribe for More Information
March 23, 2015
10:01 EDTKMIOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Allied World (AWH) initiated with a Market Perform at Keefe Bruyette... Capnia (CAPN) initiated with a Buy at Maxim... Catamaran (CTRX) initiated with a Buy at Mizuho... CyberArk (CYBR) initiated with a Buy at BofA/Merrill... Inotek Pharmaceuticals (ITEK) initiated with a Buy at Canaccord... Kinder Morgan (KMI) initiated with a Buy at Argus... MGM China (MCHVF) initiated with a Market Perform at Bernstein... Maxim Integrated (MXIM) initiated with a Buy at Summit Research... Melco Crown (MPEL) initiated with an Outperform at Bernstein... Microsemi (MSCC) initiated with an Outperform at BMO Capital... Sands China (SCHYY) initiated with an Outperform at Bernstein... Tetraphase (TTPH) initiated with a Buy at Nomura... Vista Outdoor (VSTO) initiated with a Sector Weight at KeyBanc... Wynn Macau (WYNMF) initiated with a Market Perform at Bernstein.
10:00 EDTAPAOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:46 EDTKMIKinder Morgan initiated with a Buy at Argus
Target $50.
08:15 EDTAPAApache downgraded to Neutral from Buy at Citigroup
Citigroup downgraded Apache to Neutral after resuming coverage of the stock and cut its price target for shares to $60 from $74.
March 19, 2015
16:15 EDTWMBWilliams announces FERC approval of Maryland natural gas pipeline
Williams announced that the Federal Energy Regulatory Commission has approved Transco’s application to expand its mainline pipeline system and construct an 11-mile pipeline lateral connecting Transco to an electric power generating facility in Cecil County, Md. The Rock Springs expansion project is designed to transport 192,000 dekatherms of natural gas per day to Old Dominion Electric Cooperative’s planned Wildcat Point Generation Facility. Transco’s Rock Springs expansion is among $4.8B in transmission projects Williams expects to place into service through 2017, the company noted.
March 18, 2015
10:00 EDTNIOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Columbia Pipeline (CPPL) initiated with a Buy at Citigroup... DBV Technologies (DBVT) initiated with a Buy at H.C. Wainwright... Genocea (GNCA) initiated with an Overweight at Piper Jaffray... NiSource (NI) initiated with a Neutral at JPMorgan... On Deck Capital (ONDK) initiated with a Sell at Compass Point... Rexel (RXEEY) initiated with an Overweight at Barclays... Shutterfly (SFLY) initiated with a Buy at Axiom... Virgin America (VA) initiated with an Underperform at Credit Suisse.
06:32 EDTNINiSource reinstated with an Outperform at Credit Suisse
Subscribe for More Information
06:28 EDTNINiSource initiated with a Neutral at JPMorgan
Target $46.
05:39 EDTMDTSt. Jude Medical downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo downgraded St. Jude Medical (STJ) to Market Perform saying competitive pressures will drive 2015 market share losses in the company's cardiac rhythm management business, which represents 50% of total sales. Wells believes the launch of CardioMEMS will not be strong enough to offset the headwinds in CRM unit. The firm thinks Boston Scientific's (BSX) earlier than expected approval for its next generation subcutaneous implantable cardioverter-defibrillator called Emblem will drive share gains against St. Jude and Medtronic (MDT) in the single chamber ICD market. Wells cut its price target range for St. Jude shares to $69-$70 from $73-$74. The medical technology company closed yesterday down $2.01 to $65.45.
March 16, 2015
13:16 EDTMDTAnalysts upbeat on results of Edwards' Sapien 3 data
The shares of Edwards Lifesciences (EW) are rising after the company released data on its Sapien 3 transcathter aortic valve over the weekend. In notes to investors today, a number of analysts were upbeat on the data. BACKGROUND: Edwards yesterday announced that high- and intermediate-risk patients treated with Sapien 3 demonstrated lower mortality rates than patients treated with previous transcathter aortic valves, or TAVR, made by the company. The patients also had excellent clinical outcomes in the other primary endpoints of stroke and paravalvular regurgitation, the company stated. Meanwhile, a five year study of patients treated with the first generation SAPIEN device showed that the patients had equivalent outcomes to traditional open-heart surgery, and no structural valve deterioration requiring intervention, the company stated. ANALYST REACTION: Edwards' Sapien 3 data was impressive, as the device showed one of the lowest stroke and mortality rates of any major TAVR study so far, Bernstein analyst Derrick Sung wrote in a note to investors earlier today. Data presented by Edwards and other companies at the American College of Cardiology, or ACC, conference this weekend caused investors and the medical community to become more optimistic about the potential for TAVR devices to replace surgical valves, Sung stated. The analyst wrote that he continues to believe that investors are underestimating the potential size of the TAVR market. Also upbeat on Edwards' data was Wells Fargo, which wrote that the data exceeded high expectations and could pressure the FDA to approve Sapien 3 for intermediate risk patients earlier than Edwards' guidance of late 2016. WHAT'S NOTABLE: Analysts were also upbeat on data reported by other companies at the ACC conference. Medtronic's (MDT) data suggested that its CoreValve Evolut-R product may be as effective as Edwards' Sapien 3, Bernstein's Sung stated. The FDA appears to have allowed Boston Scientific's (BSX) left atrial appendage closure, Watchman, to be provided to more patients than expected, research firm Stifel believes. Meanwhile, St. Jude's (STJ) CardioMEMS device yielded "impressive" mortality data, the firm added. Stifel kept Buy ratings on both Medtronic and St. Jude. PRICE ACTION: In early afternoon trading, Edwards Lifesciences climbed 9% to $147.64, Boston Scientific advanced 4% to $17.27, St. Jude added 2% to $67.55, and Medtronic rose 1.3% to $77.50.
09:46 EDTCNPAccenture and SAP selected by CenterPoint Energy to develop analytics solution
Subscribe for More Information
08:03 EDTWMBWilliams' Atlantic Sunrise pipeline to generate $1.6B economic impact
Subscribe for More Information
07:30 EDTMDTAmerican College of Cardiology to hold an expo
Subscribe for More Information
07:22 EDTMDTMedtronic Edwards Lifesciences data 'impressive,' says Bernstein
Subscribe for More Information
07:16 EDTCCEConsumer Analyst Group of Europe to hold a conference
Subscribe for More Information
05:42 EDTCCECoca-Cola Enterprises affirms FY15 EPS view of up 6%-8%
Subscribe for More Information
March 15, 2015
15:27 EDTMDTMedtronic unveils data from high risk study of the CoreValve U.S. pivotal trial
Subscribe for More Information
15:23 EDTMDTMedtronic unveils preclinical outcomes of its novel Drug-Filled Stent
Subscribe for More Information
15:20 EDTMDTMedtronic announces outcomes for its next-generation CoreValve Evolut R System
Medtronic announced initial clinical outcomes for its next-generation CoreValve Evolut R System. At 30-days, the new recapturable, self-expanding valve showed no incidents of all-cause mortality or stroke in a high and extreme risk patient population. Data from the Evolut R Study, which enrolled 60 patients from six centers in the United Kingdom, Australia and New Zealand, were unveiled today at the 64th Annual Scientific Session of the American College of Cardiology. The CoreValve Evolut R System is not approved for commercial use in the United States where it is currently undergoing clinical trials. "Initial clinical experience with the Evolut R system is remarkable and ushers in a new era of TAVR technology that provides increased confidence with recapturability, excellent procedural results, and impressive clinical outcomes," said Ian Meredith, M.D., of Monash Heart - Monash Health, Melbourne, Australia, who is one of the investigators of the study. "The 14 French equivalent delivery system allowed transfemoral access for most patients and the recapturable technology enabled implanters to optimize valve placement for improved annular sealing and reduced conduction disturbances without compromise on mortality or stroke."
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use